Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. on November 10, 2017, reporting an event that occurred on November 8, 2017. The company develops medical devices, specifically the Orion Cortical Visual Prosthesis System, designed to restore vision to patients blinded by conditions such as glaucoma and diabetic retinopathy.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone rather than financial performance.
Material Changes
The primary material change reported is the U.S. Food and Drug Administration (FDA) granting Expedited Access Pathway designation for the Orion Cortical Visual Prosthesis System. This designation is intended to expedite the development, assessment, and review of the device to provide more timely access for patients with life-threatening or irreversibly debilitating conditions.
Guidance, Outlook, and Management Commentary
- Regulatory Status: The company has approval for a feasibility study at two U.S. sites with a capacity to enroll up to five total patients.
- Clinical Sites: The designated U.S. clinical trial sites are the University of California, Los Angeles, and Baylor College of Medicine in Houston.
- Technology: Orion bypasses the retina and optic nerve, converting images from a camera into electrical pulses transmitted to electrodes implanted on the visual cortex.
Investor Verification Checklist
- Verify the specific criteria and benefits of the FDA Expedited Access Pathway designation for Orion.
- Confirm the enrollment status and timeline for the feasibility study at UCLA and Baylor College of Medicine.
- Review the attached press release (Exhibit 99.1) for additional details on the regulatory pathway.
- Check subsequent filings for updates on patient enrollment and study results.